Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

Supportive Care in Cancer

Volumn 4, Issue 2, 1996, Pages 141-146

  Hesketh, Paul J ^a   Gandara, David R ^b   Hesketh, Ann M ^a   Facada, Anna ^c   Perez, Edith A ^b   Webber, Lauri M ^a   Martin, Lorene A ^d   Cramer, Michael B ^d   Hahne, William F ^d  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d Marion Merrell Dow Inc   (United States)

Author keywords

Antiemetic; Dolasetron; Dose ranging trial; Emesis; Nausea

Indexed keywords

ALKYLATING AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLOPHOSPHAMIDE; DOLASETRON MESILATE; DOXORUBICIN; INDOLE DERIVATIVE; QUINOLIZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; NAUSEA; NEOPLASM; PILOT STUDY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PILOT PROJECTS; QUINOLIZINES; VOMITING;

EID: 0030097739     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01845763     Document Type: Review

References (18)

1. Baltzer L, Kris MG, Hinkley L, et al (1994) Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae? (abstract). Proc Am Soc Clin Oncol 13:433
2. Beck TM, Ciociola AA, Jones SE, et al (1993) Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118:407-413
3. 3 antagonists MDL 73147EF (dolasetron mesylate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 219:9-13
4. Boxenbaum H, Gillespie T, Heck K, Hahne W (1992) Human dolasetron pharmacokinetics. I. Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 13:693-701
5. Clark R, Tyson L, Frisone M (1985) A correlation of objective (OBJ) and subjective (SUBJ) parameters in assessing antiemetic regimens (AER). Oncol Nurs Forum 12 [Suppl]:96
6. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 17:97-102
7. Dixon R, Cramer M, Conway DW, et al (1995) Single-dose, placebo-controlled phase I study of oral dolasetron. Pharmacotherapy (in press)
8. 3 receptor antagonist (abstract). Br J Pharmacol 107 [Suppl]:449P
9. 3 antagonists incorporating a novel bridged pseudopelletierine ring system. Actual Chim Ther 16:187-189
10. Grunberg SM, Hesketh PJ (1993) Control of chemotherapv-induced emesis. N Engl J Med 329:1790-1796
11. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613-620
12. Hunt TL, Cramer M, Shah A, Stewart W, Benedict CR, Hahne WF (1995) A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 35:705-712
13. Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S (1987) Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone: a double-blind, randomized trial. Cancer 60:2816-2822
14. Kris MG, Grunberg SM, Gralla RJ. et al (1994) Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving highdose cisplatin. J Clin Oncol 12:1045-1049
15. Lifsey DS, Gralla RJ, Clark RA, Kline RC (1993) Electrocardiographic changes with serotonin antagonist antiemetics: rate of occurrence and clinical relevance (abstract). Proc Am Soc Clin Oncol 12:463
16. 3 receptors. Drug Dev Res 28:87-93
17. Plezia P, Modiano M, Alberts D, et al (1992) A double-blind, randomized, parallel study of two doses of intravenous (IV) MDL 73.147EF in patients (PTS) receiving high dose cisplatin (CDDP)-containing chemotherapy (CT) (abstract). Proc Am Soc Clin Oncol 11:407
18. 3 receptor antagonists, in anesthetized dogs. Drug Dev Res 24:277-284